ANO2

Summary

ANO2 (anoctamin 2, HGNC:1183) is a protein-coding gene on chromosome 12p13.31, encoding Anoctamin-2 (Q9NQ90). Calcium-activated chloride channel (CaCC) which may play a role in olfactory signal transduction.

ANO2 belongs to a family of calcium-activated chloride channels (CaCCs) (reviewed by Hartzell et al., 2009 [PubMed 19015192]).

Source: NCBI Gene 57101 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 30 total — 2 pathogenic
• GTEx eGene: eQTL in 27 tissues, sQTL in 7 (q < 0.05)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.02 (unconstrained)
• MANE Select transcript: NM_001364791

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1183
Approved symbol	ANO2
Name	anoctamin 2
Location	12p13.31
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000047617
Ensembl biotype	protein_coding
OMIM	610109
Entrez	57101

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 7 protein_coding_CDS_not_defined, 6 protein_coding

MANE Select: ENST00000682330

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 3: 4, TSL 4: 2, TSL 5: 3

ENST00000682330, ENST00000356134, ENST00000536751, ENST00000538154, ENST00000540543, ENST00000541487, ENST00000541874, ENST00000542326, ENST00000544988, ENST00000545860, ENST00000650848, ENST00001129547, ENST00001136573

RefSeq mRNA: 3 — MANE Select: NM_001364791 NM_001278596, NM_001278597, NM_001364791

CCDS: CCDS44807, CCDS91642, CCDS91643

Canonical transcript exons

ENST00000682330 — 25 exons

Exon	Start	End
ENSE00000369645	5575834	5576015
ENSE00000714392	5565558	5565663
ENSE00000714393	5577955	5578007
ENSE00000714395	5599484	5599629
ENSE00000714434	5615186	5615297
ENSE00000714440	5744157	5744317
ENSE00000714441	5750836	5750970
ENSE00000714442	5799507	5799571
ENSE00000714454	5806052	5806093
ENSE00001043579	5635152	5635347
ENSE00001167065	5807313	5807368
ENSE00001296413	5921040	5921366
ENSE00001302307	5827769	5827820
ENSE00001314561	5922620	5922804
ENSE00001649282	5578366	5578518
ENSE00003475792	5647727	5647801
ENSE00003483300	5612656	5612756
ENSE00003506281	5732520	5732630
ENSE00003548353	5612901	5612958
ENSE00003559502	5830435	5830489
ENSE00003563197	5739317	5739399
ENSE00003656372	5854043	5854141
ENSE00003671636	5832452	5832603
ENSE00003720946	5945196	5945259
ENSE00003919205	5562655	5563568

Expression profiles

Bgee: expression breadth ubiquitous, 165 present calls, max score 89.19.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.3565 / max 122.5880, expressed in 101 samples.

Highest expression (Bgee): sural nerve, testis, calcaneal tendon, male germ line stem cell (sensu Vertebrata) in testis, primordial germ cell in gonad.

Genetic regulation across tissues (GTEx eQTL / sQTL)

ANO2 is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 27 tissues and its splicing (sQTL) in 7 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

showing 20 of 34 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Testis	sqtl	3.7e-16	+0.65	12:5600399:G:A
Skin Sun Exposed Lower leg	eqtl	1.2e-15	-0.26	12:5937460:ACTT:A
Adipose Subcutaneous	eqtl	6.5e-14	+0.28	12:5953687:C:T
Muscle Skeletal	eqtl	3.9e-13	-0.33	12:5938554:C:T
Skin Not Sun Exposed Suprapubic	eqtl	9.0e-13	+0.27	12:5962603:T:C
Nerve Tibial	eqtl	5.4e-12	-0.27	12:5936095:T:C
Esophagus Mucosa	eqtl	1.3e-11	-0.39	12:5947326:T:C
Thyroid	eqtl	2.0e-11	-0.28	12:5924756:T:C
Colon Transverse	eqtl	3.5e-11	-0.25	12:5936095:T:C
Adipose Visceral Omentum	eqtl	1.1e-09	-0.23	12:5936095:T:C
Heart Atrial Appendage	eqtl	2.1e-09	-0.25	12:5940870:A:C
Colon Sigmoid	eqtl	2.2e-09	-0.26	12:5936095:T:C
Esophagus Muscularis	eqtl	9.9e-09	-0.25	12:5927515:G:A
Artery Aorta	eqtl	1.8e-08	-0.28	12:5924756:T:C
Breast Mammary Tissue	eqtl	3.3e-08	+0.19	12:5948745:A:G
Lung	eqtl	1.1e-07	-0.23	12:5937460:ACTT:A
Spleen	eqtl	4.0e-07	-0.69	12:6176637:G:A
Adipose Subcutaneous	sqtl	5.7e-07	+0.41	12:5609057:C:T
Brain Cerebellum	eqtl	8.0e-07	-0.31	12:5930247:A:G
Heart Left Ventricle	eqtl	5.4e-06	-0.26	12:5947284:G:T

FANTOM5 promoters

3 alternative TSS:

Promoter ID	TPM avg	Samples expressed
129038	0.2155	75
129039	0.1116	23
129035	0.0294	11

Top tissues by expression

showing 100 of 285 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
sural nerve	UBERON:0015488	89.19	gold quality
left testis	UBERON:0004533	86.43	gold quality
calcaneal tendon	UBERON:0003701	86.17	gold quality
right testis	UBERON:0004534	85.94	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.84	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	82.77	gold quality
testis	UBERON:0000473	82.37	gold quality
apex of heart	UBERON:0002098	82.21	gold quality
omental fat pad	UBERON:0010414	81.91	gold quality
peritoneum	UBERON:0002358	81.80	gold quality
right lung	UBERON:0002167	80.66	gold quality
adipose tissue of abdominal region	UBERON:0007808	79.84	gold quality
upper lobe of left lung	UBERON:0008952	77.91	gold quality
right atrium auricular region	UBERON:0006631	76.51	gold quality
heart left ventricle	UBERON:0002084	76.29	gold quality
upper lobe of lung	UBERON:0008948	75.84	gold quality
endocervix	UBERON:0000458	75.41	gold quality
subcutaneous adipose tissue	UBERON:0002190	75.21	gold quality
cardiac ventricle	UBERON:0002082	75.15	gold quality
tendon	UBERON:0000043	75.14	gold quality
ectocervix	UBERON:0012249	74.69	gold quality
cardiac atrium	UBERON:0002081	74.31	gold quality
heart	UBERON:0000948	73.47	gold quality
mucosa of stomach	UBERON:0001199	72.91	gold quality
left coronary artery	UBERON:0001626	72.52	gold quality
body of uterus	UBERON:0009853	72.51	gold quality
lower esophagus muscularis layer	UBERON:0035833	72.41	gold quality
lower esophagus	UBERON:0013473	72.34	gold quality
right coronary artery	UBERON:0001625	72.26	gold quality
adipose tissue	UBERON:0001013	71.92	gold quality
muscle of leg	UBERON:0001383	71.84	gold quality
gastrocnemius	UBERON:0001388	71.83	gold quality
tibial nerve	UBERON:0001323	71.48	gold quality
colonic epithelium	UBERON:0000397	71.31	gold quality
ventricular zone	UBERON:0003053	71.25	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	71.23	gold quality
connective tissue	UBERON:0002384	71.06	gold quality
coronary artery	UBERON:0001621	70.75	gold quality
tibial artery	UBERON:0007610	70.35	gold quality
popliteal artery	UBERON:0002250	70.29	gold quality
right ovary	UBERON:0002118	70.11	gold quality
left uterine tube	UBERON:0001303	70.09	gold quality
hindlimb stylopod muscle	UBERON:0004252	70.02	gold quality
vagina	UBERON:0000996	69.67	gold quality
aorta	UBERON:0000947	69.65	gold quality
pigmented layer of retina	UBERON:0001782	69.28	gold quality
ascending aorta	UBERON:0001496	69.24	gold quality
thoracic aorta	UBERON:0001515	69.21	gold quality
esophagus	UBERON:0001043	69.14	gold quality
placenta	UBERON:0001987	69.03	gold quality
descending thoracic aorta	UBERON:0002345	68.82	gold quality
left lobe of thyroid gland	UBERON:0001120	68.51	gold quality
muscle layer of sigmoid colon	UBERON:0035805	68.49	gold quality
lower esophagus mucosa	UBERON:0035834	68.49	gold quality
caudate nucleus	UBERON:0001873	68.40	gold quality
right lobe of thyroid gland	UBERON:0001119	68.25	gold quality
body of stomach	UBERON:0001161	68.19	gold quality
nucleus accumbens	UBERON:0001882	68.10	gold quality
spleen	UBERON:0002106	67.73	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	67.56	gold quality
thyroid gland	UBERON:0002046	67.49	gold quality
putamen	UBERON:0001874	67.37	gold quality
right frontal lobe	UBERON:0002810	67.21	gold quality
left ovary	UBERON:0002119	67.13	gold quality
stomach	UBERON:0000945	67.01	gold quality
esophagus mucosa	UBERON:0002469	66.64	gold quality
muscle organ	UBERON:0001630	66.59	gold quality
smooth muscle tissue	UBERON:0001135	66.08	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	66.08	gold quality
lung	UBERON:0002048	65.86	gold quality
ganglionic eminence	UBERON:0004023	65.69	gold quality
fundus of stomach	UBERON:0001160	65.33	gold quality
gall bladder	UBERON:0002110	65.08	gold quality
spinal cord	UBERON:0002240	64.93	gold quality
uterine cervix	UBERON:0000002	64.87	gold quality
anterior cingulate cortex	UBERON:0009835	64.70	gold quality
amygdala	UBERON:0001876	64.68	gold quality
cingulate cortex	UBERON:0003027	64.64	gold quality
minor salivary gland	UBERON:0001830	64.60	gold quality
metanephros cortex	UBERON:0010533	64.40	gold quality
skin of abdomen	UBERON:0001416	64.10	gold quality
skin of leg	UBERON:0001511	63.92	gold quality
transverse colon	UBERON:0001157	63.83	gold quality
small intestine Peyer’s patch	UBERON:0003454	63.77	gold quality
ovary	UBERON:0000992	63.02	gold quality
cerebellar hemisphere	UBERON:0002245	62.93	gold quality
right hemisphere of cerebellum	UBERON:0014890	62.92	gold quality
pancreatic ductal cell	CL:0002079	62.73	silver quality
cerebellar cortex	UBERON:0002129	62.69	gold quality
hypothalamus	UBERON:0001898	62.58	gold quality
anatomical system	UBERON:0000467	62.57	gold quality
small intestine	UBERON:0002108	62.51	gold quality
prefrontal cortex	UBERON:0000451	62.47	gold quality
multicellular organism	UBERON:0000468	62.38	gold quality
material anatomical entity	UBERON:0000465	62.35	gold quality
prostate gland	UBERON:0002367	62.20	gold quality
colon	UBERON:0001155	62.19	gold quality
myometrium	UBERON:0001296	61.98	gold quality
female reproductive system	UBERON:0000474	61.75	gold quality
right uterine tube	UBERON:0001302	61.75	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-11268	yes	2693.27
E-HCAD-35	yes	22.03
E-ANND-3	no	0.00

HPA expression

RNA tissue specificity: Tissue enriched

showing 60 of 69 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Retina	tissue	190.9	low
Basal ganglia	tissue	19.6	not detected
Septum	tissue	19.6
Caudate putamen	tissue	17.8
Choroid plexus	tissue	9.0
Testis	tissue	8.6	not detected
Ventral forebrain	tissue	7.1
Nucleus accumbens	tissue	6.3
Putamen	tissue	5.8
Medulla oblongata	tissue	5.7
Substantia nigra	tissue	5.1
Spinal cord	tissue	5.0
Amygdala	tissue	4.6
Locus coeruleus	tissue	3.7
Hippocampus	tissue	3.4	not detected
Tongue	tissue	3.0
Placenta	tissue	2.9	not detected
Entorhinal cortex	tissue	2.6
Retrosplenial cortex	tissue	2.6
Adipose tissue	tissue	2.4	not detected
Postcentral gyrus	tissue	2.1
Heart muscle	tissue	2.0	not detected
Pons	tissue	1.7
Hippocampal formation	tissue	1.7
Lung	tissue	1.5	not detected
Skeletal muscle	tissue	1.4	not detected
Cervix	tissue	1.3	not detected
Cerebral cortex	tissue	1.1	not detected
Smooth muscle	tissue	1.1	not detected
Frontal cortex	tissue	1.1
Spleen	tissue	1.1	not detected
Corpus callosum	tissue	1.1
Breast	tissue	1.0	not detected
Parathyroid gland	tissue	1.0	not detected
Endometrium 1	tissue	0.9	not detected
Epididymis	tissue	0.9	not detected
Fallopian tube	tissue	0.9	high
Thalamus	tissue	0.8
Seminal vesicle	tissue	0.7	not detected
Thyroid gland	tissue	0.7	not detected
Occipital cortex	tissue	0.7
Ovary	tissue	0.6	not detected
Urinary bladder	tissue	0.6	not detected
Hypothalamus	tissue	0.6
Small intestine	tissue	0.6	not detected
Gallbladder	tissue	0.6	not detected
Esophagus	tissue	0.5	not detected
Stomach 1	tissue	0.4	not detected
Rectum	tissue	0.4	not detected
Colon	tissue	0.4	not detected
Prostate	tissue	0.4	not detected
Skin 1	tissue	0.3	not detected
Vagina	tissue	0.3	not detected
Salivary gland	tissue	0.3	not detected
Kidney	tissue	0.3	not detected
Duodenum	tissue	0.3	not detected
Somatosensory cortex	tissue	0.3
Appendix	tissue	0.3	not detected
Pancreas	tissue	0.2	not detected
Thymus	tissue	0.2

Brain sub-regions (HPA Brain Atlas): detected in 185; highest nTPM — Nucleus basalis of Meynert (7.6), Posterior thalamic nucleus (7.3), Lateral amygdala (6.6), Caudate nucleus (6.4), Motor trigeminal nucleus (6.2).

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): FOXA2, MYCN

Functional genomics

gnomAD constraint: pLI 1.03e-30, LOEUF 1.02, missense Z -0.0956 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000682330 — one region, missense o/e 1.01.

Literature-anchored findings (GeneRIF, showing 13)

• C12orf3, FLJ10261 (ORAOV2), C11orf25 and FLJ34272 constitute a family of eight-transmembrane proteins with N- and C-terminal tails facing the cytoplasm. (PMID:12739008)
• VWF and TMEM16B deletions may have a role in severe von Willebrand disease type 3 (PMID:17371490)
• This study suggested that TMEM16B to be a strong candidate for the long sought-after Ca(2+)-dependent chloride channel in the photoreceptor synapse. (PMID:19474308)
• Ano2 likely amplifies the odor-induced generator potential in olfactory sensory neuron cilia by sensing elevated calcium levels, permitting the outward flow of chloride ions from the cell. (PMID:19561302)
• The third intracellular loop of TMEM16B is the site involved in calcium ion sensitivity, whereas the C-terminal part affects the rate of transition between the open and the closed state of the channel. (PMID:23570556)
• ANO2 is present in human myometrium. (PMID:24928056)
• results reveal multidimensional regulation of TMEM16A/16B by preassociated apoCaM and introduce ChIMP as a versatile tool to probe the macromolecular complex and function of Ca(2+)-activated chloride channels (PMID:25489088)
• Olfactory function impairment in Italian patients with type 3 von Willebrand disease with partial deletion of TMEM16B. (PMID:25635880)
• data revealed prominently increased autoantibody reactivity against the chloride-channel protein anoctamin 2 (ANO2) in multiple sclerosis cases compared with controls (PMID:26862169)
• residues facing the putative channel pore are responsible both for controlling the ion selectivity and the gating of the channel, providing an initial understanding of molecular mechanism of ion permeation in TMEM16B (PMID:28046119)
• a hypothesis where immune reactivity toward EBNA1 through molecular mimicry with ANO2 contributes to the etiopathogenesis of Multiple sclerosis. (PMID:31375628)
• Anoctamin 2-chloride channels reduce simple spike activity and mediate inhibition at elevated calcium concentration in cerebellar Purkinje cells. (PMID:33651839)
• Modulation of TMEM16B channel activity by the calcium-activated chloride channel regulator 4 (CLCA4) in human cells. (PMID:38825009)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	ano2a	ENSDARG00000003210
danio_rerio	ano2b	ENSDARG00000101363
danio_rerio		ENSDARG00000112349
mus_musculus	Ano2	ENSMUSG00000038115
rattus_norvegicus	Ano2	ENSRNOG00000023561

Paralogs (10): ANO8 (ENSG00000074855), PPP1R7 (ENSG00000115685), ANO1 (ENSG00000131620), ANO3 (ENSG00000134343), ANO7 (ENSG00000146205), ANO4 (ENSG00000151572), ANO10 (ENSG00000160746), ANO5 (ENSG00000171714), ANO6 (ENSG00000177119), ANO9 (ENSG00000185101)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:2387214) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 10 distinct phenotype terms.

Mouse phenotype (MP)	Records
enlarged lymph nodes	1
abnormal thymus morphology	1
enlarged thymus	1
decreased anxiety-related response	1
hyperactivity	1
abnormal olfactory system physiology	1
abnormal digit morphology	1
abnormal lymph node morphology	1
abnormal behavior	1
decreased thigmotaxis	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Bos taurus	A6QLE6	95.0%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
SNORA120	snoRNA	109729112
NTF3	protein-coding	4908
VWF	protein-coding	7450
LINC02443	ncRNA	101929584

Protein

Protein identifiers

Anoctamin-2 — Q9NQ90 (reviewed: Q9NQ90)

Alternative names: Transmembrane protein 16B

All UniProt accessions (3): A0A804HIY3, F5H806, Q9NQ90

UniProt curated annotations — full annotation on UniProt →

Function. Calcium-activated chloride channel (CaCC) which may play a role in olfactory signal transduction. Odorant molecules bind to odor-sensing receptors (OSRs), leading to an increase in calcium entry that activates CaCC current which amplifies the depolarization of the OSR cells, ANO2 seems to be the underlying chloride channel involved in this process. May mediate light perception amplification in retina.

Subunit / interactions. Homodimer. Component of a presynaptic protein complex recruited to specialized plasma membrane domains of photoreceptors. Interacts with DLG4 by its C-terminal region.

Subcellular location. Cell membrane.

Tissue specificity. Retina, especially in the photoreceptor synaptic terminals.

Activity regulation. Channel activity is repressed by chloride inhibitors; strongly by niflumic acid (NFA), partially by flufenamic acid (FFA), and only slightly by meclofenamic acid (MFA), 5-Nitro-2-(3-phenylpropylamino)benzoic acid (NPPB), 4-acetamido-4’-isothiocyanato-stilben-2,2’-disulfonate (SITS), and 4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS).

Miscellaneous. The term ‘anoctamin’ was coined because these channels are anion selective and have eight (OCT) transmembrane segments. There is some dissatisfaction in the field with the Ano nomenclature because it is not certain that all the members of this family are anion channels or have the 8-transmembrane topology. Splice site between exons 4 and 5 is non-canonical. Splice site between exons 4 and 5 is non-canonical. A molecular mimicry between ANO2 and Epstein-Barr virus EBNA1 could possibly be linked to multiple sclerosis in the host.

Similarity. Belongs to the anoctamin family.

Isoforms (3)

UniProt ID	Names	Canonical?
Q9NQ90-4	1	yes
Q9NQ90-1	2
Q9NQ90-2	3

RefSeq proteins (3): NP_001265525, NP_001265526, NP_001351720* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR007632	Anoctamin	Family
IPR032394	Anoct_dimer	Domain
IPR049452	Anoctamin_TM	Domain

Pfam: PF04547, PF16178

Catalyzed reactions (Rhea)

• chloride(in) = chloride(out) (RHEA:29823)

UniProt features (34 total): topological domain 9, transmembrane region 8, glycosylation site 4, sequence variant 4, splice variant 3, region of interest 2, compositionally biased region 2, chain 1, short sequence motif 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NQ90-F1	74.81	0.26

Human Protein Atlas

Protein class: Transporters, Transporter channels and pores, Predicted membrane proteins

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): plasma membrane; nucleoplasm

Antibody reliability (HPA): IH enhanced · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (4)

Type	Positions
N-linked (glcnac…) asparagine	421, 836, 844, 851

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 12; 7 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

12 pathways:

ID	Pathway	Evidence
R-HSA-9733458	Induction of Cell-Cell Fusion ⚕	curated
R-HSA-2672351	Stimuli-sensing channels	curated
R-HSA-1643685	Disease ⚕	—
R-HSA-5663205	Infectious disease ⚕	—
R-HSA-9772573	Late SARS-CoV-2 Infection Events ⚕	—
R-HSA-9679506	SARS-CoV Infections ⚕	—
R-HSA-9694516	SARS-CoV-2 Infection ⚕	—
R-HSA-9824446	Viral Infection Pathways ⚕	—
R-HSA-983712	Ion channel transport	—
R-HSA-381753	Olfactory Signaling Pathway	electronic
R-HSA-9709957	Sensory Perception	—
R-HSA-382551	Transport of small molecules	—

MSigDB gene sets: 76 (showing top): GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, GOBP_INORGANIC_ANION_TRANSPORT, GOBP_CHLORIDE_TRANSPORT, GOBP_TRANSMEMBRANE_TRANSPORT, SHEN_SMARCA2_TARGETS_DN, SENESE_HDAC3_TARGETS_DN, GOCC_CHLORIDE_CHANNEL_COMPLEX, GOCC_TRANSPORTER_COMPLEX, GOCC_MEMBRANE_PROTEIN_COMPLEX, GOMF_PROTEIN_DIMERIZATION_ACTIVITY, GOMF_GATED_CHANNEL_ACTIVITY, GOMF_PASSIVE_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_MONOATOMIC_ANION_CHANNEL_ACTIVITY, GOMF_MONOATOMIC_ANION_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOMF_TRANSPORTER_ACTIVITY

GO Biological Process (4): monoatomic ion transmembrane transport (GO:0034220), chloride transmembrane transport (GO:1902476), monoatomic ion transport (GO:0006811), chloride transport (GO:0006821)

GO Molecular Function (4): intracellularly calcium-gated chloride channel activity (GO:0005229), chloride channel activity (GO:0005254), protein dimerization activity (GO:0046983), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), chloride channel complex (GO:0034707), membrane (GO:0016020)

Reactome top-level categories

9 top-level categories:

Category	Pathways
Ion channel transport	1
Sensory Perception	1
Late SARS-CoV-2 Infection Events	1
Disease	1
Viral Infection Pathways	1
SARS-CoV Infections	1
SARS-CoV-2 Infection	1
Infectious disease	1
Transport of small molecules	1

GO top-level categories

18 GO namespaces:

Category	Terms
monoatomic ion transport	1
transmembrane transport	1
chloride transport	1
monoatomic anion transmembrane transport	1
transport	1
monoatomic anion transport	1
inorganic anion transport	1
chloride channel activity	1
ligand-gated monoatomic anion channel activity	1
intracellularly calcium-gated channel activity	1
monoatomic anion channel activity	1
chloride transmembrane transporter activity	1
protein binding	1
binding	1
membrane	1
cell periphery	1
monoatomic ion channel complex	1
cellular anatomical structure	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 3 of 11 annotations. The rest are phylogenetic / computational / electronic (IEA).

3 experimentally-supported GO terms:

GO term	NS	Evidence
plasma membrane	CC	direct assay
intracellularly calcium-gated chloride channel activity	MF	direct assay
protein dimerization activity	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 662 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANO2	CLCA4	Q14CN2	971
ANO2	CLCA2	Q9UQC9	953
ANO2	CLCA1	A8K7I4	893
ANO2	CNGA2	Q16280	773
ANO2	CNGA4	Q8IV77	699
ANO2	RTP2	Q5QGT7	595
ANO2	ADCY3	O60266	529
ANO2	OMP	P47874	499
ANO2	HEPACAM	Q14CZ8	490
ANO2	GNAL	P38405	484
ANO2	RTP1	P59025	443
ANO2	OR4D2	P58180	441
ANO2	FAM162B	Q5T6X4	433
ANO2	OR2Y1	Q8NGV0	432
ANO2	ZNF70	Q9UC06	431

IntAct

Human interaction partners of ANO2 in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

1 partners by confidence:

Partner	Interaction type	MIscore	Records
DLG1	direct interaction	0.440	2

BioGRID (8 interactions; top human partners by supporting records): CLIC1 (Affinity Capture-MS), KIAA1429 (Affinity Capture-RNA), KIF14 (Affinity Capture-MS), PARP1 (Proximity Label-MS), PARP12 (Proximity Label-MS), PARP2 (Proximity Label-MS), PARP9 (Proximity Label-MS), TIPARP (Proximity Label-MS)

Disease & clinical

Genetic variants

Variant evidence for ANO2: 30 ClinVar records (2 pathogenic / likely pathogenic); 18 PharmGKB clinical annotations; 9 GWAS associations. Per-variant detail is on Sugi Variant.

ClinVar

30 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	4
Likely benign	4
Benign	2

Top pathogenic / likely-pathogenic (2)

Showing all 2 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
1330180	GRCh37/hg19 12p13.33-13.31(chr12:146240-8330229)x3	Pathogenic	criteria provided, single submitter	1
1527679	GRCh37/hg19 12p13.31(chr12:6024262-6276970)x1	Pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore ANO2’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 41 predictions of 3,037):

Position(s)	Effect	Δscore	Sites
12:5563569–5563570	acceptor_loss	1.0000	6
12:5563573	acceptor_gain	1.0000
12:5599487–5599489	donor_gain	1.0000	2
12:5599630–5599631	acceptor_loss	1.0000	4
12:5612757–5612758	acceptor_loss	1.0000	6
12:5615184–5615185	donor_loss	1.0000	5
12:5615188	donor_gain	1.0000
12:5615298–5615299	acceptor_loss	1.0000	6
12:5732518–5732519	donor_loss	1.0000	4
12:5732631–5732632	acceptor_loss	1.0000	6

AlphaMissense

2,520 missense substitutions predicted likely pathogenic (of 6,620 scored), across 598 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
M749	9	0.898	0.986
M448	9	0.865	0.987
D781	8	0.997	0.998
D100	8	0.993	0.997
H316	8	0.993	0.998
D733	8	0.986	0.996
F759	8	0.986	0.998
F273	8	0.984	0.997
H190	8	0.982	0.999
F364	8	0.981	0.999
N693	8	0.977	0.997
F763	8	0.974	0.994
F256	8	0.970	0.999
N774	8	0.953	0.999
F92	8	0.951	0.991
D437	8	0.951	0.981
F356	8	0.948	0.997
F455	8	0.948	0.997
F909	8	0.947	0.992
N773	8	0.946	0.998

HPA cancer prognostics

RNA cancer specificity: Cancer enhanced (Testicular Germ Cell Tumor)

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

1 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (validation)	favorable	0.000364

Disease associations

OMIM: gene MIM:610109 | disease phenotypes:

GWAS associations

9 associations:

Study	Trait	p-value
GCST000320_7	Panic disorder	4e-9
GCST002925_5	Sex hormone levels	2e-8
GCST010703_195	Brain morphology (MOSTest)	3e-8
GCST001762_753	Obesity-related traits	3e-6
GCST003133_3	Plasma clusterin levels	3e-6
GCST009391_1299	Metabolite levels	5e-6
GCST011038_7	Parkinson’s disease progression (motor)	6e-6
GCST004751_25	Serum uric acid levels in response to allopurinol in gout	7e-6
GCST009542_1	Cleft lip with or without cleft palate x maternal periconceptional alcohol use interaction (parent of origin effect)	7e-6

EFO canonical traits (from GWAS)

11 canonical traits:

EFO ID	Trait name
EFO:0003940	physical activity
EFO:0004697	estradiol measurement
EFO:0004730	hormone measurement
EFO:0007656	plasma clusterin measurement
EFO:0004761	uric acid measurement
EFO:0010523	phosphoglyceric acid measurement
EFO:0003959	cleft lip
EFO:0005939	parental genotype effect measurement
EFO:0009113	alcohol exposure measurement
EFO:0004346	neuroimaging measurement
EFO:0008336	disease progression measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4105767 (SINGLE PROTEIN)

PharmGKB: 1 entry (CPIC guideline: no)

PharmGKB clinical annotations

18 annotations by evidence level (1 strongest → 4):

Variant	Association	Level	Drugs	Phenotypes
rs17724452	Efficacy	3	duloxetine	Major Depressive Disorder
rs17724464	Efficacy	3	duloxetine	Major Depressive Disorder
rs17724494	Efficacy	3	duloxetine	Major Depressive Disorder
rs17786394	Efficacy	3	duloxetine	Major Depressive Disorder
rs17786400	Efficacy	3	duloxetine	Major Depressive Disorder
rs17786412	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908402	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908403	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908404	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908405	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908406	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908407	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908408	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908409	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908410	Efficacy	3	duloxetine	Major Depressive Disorder
rs61908411	Efficacy	3	duloxetine	Major Depressive Disorder
rs78482393	Efficacy	3	duloxetine	Major Depressive Disorder
rs78615940	Efficacy	3	duloxetine	Major Depressive Disorder

PharmGKB variants

18 variants:

Variant	Genes	Level	Score	#Clin annots	Drugs
rs17724452	ANO2	3	0.00	1	duloxetine
rs17724464	ANO2	3	0.00	1	duloxetine
rs17724494	ANO2	3	0.00	1	duloxetine
rs17786394	ANO2	3	0.00	1	duloxetine
rs17786400	ANO2	3	0.00	1	duloxetine
rs17786412	ANO2	3	0.00	1	duloxetine
rs61908402	ANO2	3	0.00	1	duloxetine
rs61908403	ANO2	3	0.00	1	duloxetine
rs61908404	ANO2	3	0.00	1	duloxetine
rs61908405	ANO2	3	0.00	1	duloxetine
rs61908406	ANO2	3	0.00	1	duloxetine
rs61908407	ANO2	3	0.00	1	duloxetine
rs61908408	ANO2	3	0.00	1	duloxetine
rs61908409	ANO2	3	0.00	1	duloxetine
rs61908410	ANO2	3	0.00	1	duloxetine
rs61908411	ANO2	3	0.00	1	duloxetine
rs78482393	ANO2	3	0.00	1	duloxetine
rs78615940	ANO2	3	0.00	1	duloxetine

PharmGKB variant annotations

Per-publication pharmacogenomic findings for this gene (significant associations).

19 published findings:

Variant	Drug(s)	Category	Finding	PMID
rs17724452	duloxetine	Efficacy	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	PMID:29407288
rs17724464	duloxetine	Efficacy	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	PMID:29407288
rs17724494	duloxetine	Efficacy	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	PMID:29407288
rs17786394	duloxetine	Efficacy	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	PMID:29407288
rs17786400	duloxetine	Efficacy	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	PMID:29407288
rs17786412	duloxetine	Efficacy	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	PMID:29407288
rs61908402	duloxetine	Efficacy	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	PMID:29407288
rs61908403	duloxetine	Efficacy	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	PMID:29407288
rs61908404	duloxetine	Efficacy	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	PMID:29407288
rs61908405	duloxetine	Efficacy	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	PMID:29407288
rs61908406	duloxetine	Efficacy	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	PMID:29407288
rs61908407	duloxetine	Efficacy	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	PMID:29407288
rs61908408	duloxetine	Efficacy	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	PMID:29407288
rs61908409	duloxetine	Efficacy	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele G.	PMID:29407288
rs61908410	duloxetine	Efficacy	Allele T is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	PMID:29407288
rs61908411	duloxetine	Efficacy	Allele C is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele T.	PMID:29407288
rs78482393	duloxetine	Efficacy	Allele G is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele A.	PMID:29407288
rs78615940	duloxetine	Efficacy	Allele A is associated with decreased response to duloxetine in people with Depressive Disorder, Major as compared to allele C.	PMID:29407288
rs2110166	aflibercept, ranibizumab	Efficacy	Genotype TT is associated with increased clinical benefit to aflibercept or ranibizumab in people with Macular Degeneration as compared to genotypes CC + CT.	PMID:38980270

Binding affinities (BindingDB)

20 measured of 30 human assays (30 total across all organisms); most potent 20 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
CHEMBL5186789	IC50	24 nM
CHEMBL4074929	IC50	30 nM
2-(4-chloro-2-methylphenoxy)-N-[(E)-(2-methoxyphenyl)methylideneamino]acetamide	IC50	110 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
CHEMBL3134585	IC50	130 nM
CHEMBL4104024	IC50	150 nM
CHEMBL4071143	IC50	180 nM
CHEMBL1444023	IC50	260 nM
2-(4-chloro-2-methylphenoxy)-N-[(E)-1-[2-(trifluoromethoxy)phenyl]ethylideneamino]acetamide	IC50	300 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
CHEMBL4085154	IC50	600 nM
CHEMBL1299863	IC50	1000 nM
CHEMBL4086165	IC50	1600 nM
2-(4-chloro-2-methylphenoxy)-N’-[(2-methoxyphenyl)methyl]acetohydrazide	IC50	10700 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
ethyl 2-[[2-(4-chloro-2-methylphenoxy)acetyl]amino]-1,3-thiazole-4-carboxylate	IC50	14800 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
ethyl 2-[2-[(E)-[[2-(4-chloro-2-methylphenoxy)acetyl]hydrazinylidene]methyl]phenoxy]-2-fluoroacetate	IC50	15700 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
2-[(4-chloro-2-methylphenoxy)methyl]-5-(2-methoxyphenyl)-1,3,4-oxadiazole	IC50	19400 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
2-(4-chloro-2-methylphenoxy)-N-[(2-methoxyphenyl)methyl]acetamide	IC50	20600 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
2-[(4-chloro-2-methylphenoxy)methyl]-5-(2-fluorophenyl)-1,3,4-oxadiazole	IC50	21200 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
2-(4-chloro-2-methylphenoxy)-N-[(E)-pyridin-2-ylmethylideneamino]acetamide	IC50	31300 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
2-(4-chloro-2-methylphenoxy)-N-[(3-methoxyphenyl)methyl]acetamide	IC50	53700 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity
2-[(4-chloro-2-methylphenoxy)methyl]-5-(furan-2-yl)-1,3,4-oxadiazole	IC50	63800 nM	US-11274074: Pharmaceutical composition for ANO1 antagonist with anticancer activity

ChEMBL bioactivities

8 potent at pChembl≥5 of 14 total, top 8 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.40	IC50	400	nM	CHEMBL4071143
6.40	IC50	400	nM	CHEMBL4074929
5.96	IC50	1100	nM	CHEMBL4104024
5.85	IC50	1400	nM	CHEMBL1444023
5.85	IC50	1400	nM	CHEMBL4085154
5.40	IC50	4000	nM	CHEMBL1299863
5.34	IC50	4600	nM	CHEMBL3134585
5.06	IC50	8700	nM	CHEMBL5186789

PubChem BioAssay actives

8 with measured affinity, of 52 total; 8 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(2-bromo-2,2-difluoroacetyl)amino]-N-(2-methylphenyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide	1448056: Inhibition of human TMEM16B expressed in FRT cells co-expressing iodide sensitive fluorescent protein YFP-H148Q/I152L/F46L assessed as reduction in ATP-induced Ca2+ activation-mediated chloride current by measuring decrease in iodide influx preincubated for 10 mins followed by ATP/iodide addition by fluorescence assay	ic50	0.4000	uM
2-[(2-chloro-2,2-difluoroacetyl)amino]-N-(2-methylphenyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide	1448056: Inhibition of human TMEM16B expressed in FRT cells co-expressing iodide sensitive fluorescent protein YFP-H148Q/I152L/F46L assessed as reduction in ATP-induced Ca2+ activation-mediated chloride current by measuring decrease in iodide influx preincubated for 10 mins followed by ATP/iodide addition by fluorescence assay	ic50	0.4000	uM
2-[(2,2-difluoro-2-iodoacetyl)amino]-N-(4-fluorophenyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide	1448056: Inhibition of human TMEM16B expressed in FRT cells co-expressing iodide sensitive fluorescent protein YFP-H148Q/I152L/F46L assessed as reduction in ATP-induced Ca2+ activation-mediated chloride current by measuring decrease in iodide influx preincubated for 10 mins followed by ATP/iodide addition by fluorescence assay	ic50	1.1000	uM
N-(2-methylphenyl)-2-[(2,2,2-trifluoroacetyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide	1448056: Inhibition of human TMEM16B expressed in FRT cells co-expressing iodide sensitive fluorescent protein YFP-H148Q/I152L/F46L assessed as reduction in ATP-induced Ca2+ activation-mediated chloride current by measuring decrease in iodide influx preincubated for 10 mins followed by ATP/iodide addition by fluorescence assay	ic50	1.4000	uM
2-[(2,2-difluoro-2-iodoacetyl)amino]-N-(2-methylphenyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide	1448056: Inhibition of human TMEM16B expressed in FRT cells co-expressing iodide sensitive fluorescent protein YFP-H148Q/I152L/F46L assessed as reduction in ATP-induced Ca2+ activation-mediated chloride current by measuring decrease in iodide influx preincubated for 10 mins followed by ATP/iodide addition by fluorescence assay	ic50	1.4000	uM
2-[(5-ethyl-4-methyl-6-oxo-1H-pyrimidin-2-yl)sulfanyl]-N-[4-(4-methoxyphenyl)-1,3-thiazol-2-yl]acetamide	1448075: Inhibition of TMEM16B (unknown origin) expressed in FRT cells assessed as reduction of ATP-induced chloride conductance preincubated for 20 mins followed by ATP addition by short-circuit current assay	ic50	4.0000	uM
N-phenyl-2-[(2,2,2-trifluoroacetyl)amino]-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide	1448056: Inhibition of human TMEM16B expressed in FRT cells co-expressing iodide sensitive fluorescent protein YFP-H148Q/I152L/F46L assessed as reduction in ATP-induced Ca2+ activation-mediated chloride current by measuring decrease in iodide influx preincubated for 10 mins followed by ATP/iodide addition by fluorescence assay	ic50	4.6000	uM
4-(4-chlorophenyl)-2-[(2,5-difluorobenzoyl)amino]thiophene-3-carboxylic acid	1868466: Inhibition of human ANO2 expressed in HEK293 cells incubated for 5 mins by whole cell patch clamp electrophysiology	ic50	8.7000	uM

CTD chemical–gene interactions

17 total (human), top 17 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects methylation, decreases expression	2
Valproic Acid	decreases expression	2
bisphenol A	affects cotreatment, decreases methylation	1
sulforaphane	decreases expression	1
benzo(e)pyrene	increases methylation	1
aflatoxin B2	increases methylation	1
nickel sulfate	decreases expression	1
CGP 52608	affects binding, increases reaction	1
2-palmitoylglycerol	increases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Benzo(a)pyrene	increases methylation	1
Doxorubicin	decreases expression	1
Methapyrilene	increases methylation	1
Methotrexate	decreases expression	1
Smoke	decreases expression	1
Tretinoin	decreases expression	1
Aflatoxin B1	affects methylation	1

ChEMBL screening assays

8 unique, capped per target: 5 binding, 3 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4015869	Binding	Inhibition of human TMEM16B expressed in FRT cells co-expressing iodide sensitive fluorescent protein YFP-H148Q/I152L/F46L assessed as reduction in ATP-induced Ca2+ activation-mediated chloride current by measuring decrease in iodide influx	Substituted 2-Acylaminocycloalkylthiophene-3-carboxylic Acid Arylamides as Inhibitors of the Calcium-Activated Chloride Channel Transmembrane Protein 16A (TMEM16A). — *J Med Chem*
CHEMBL4310425	ADMET	Inhibition of YFP-fused ANO2 (unknown origin) expressed in FRT cells after 20 mins by fluorescence quenching method	Synthesis and biological evaluation of novel Ani9 derivatives as potent and selective ANO1 inhibitors. — *Eur J Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

showing 60 of 300 trials:

NCT	Phase	Status	Title
NCT00076362	Phase 4	COMPLETED	Pediatric Hypothalamic Obesity
NCT00079547	Phase 4	COMPLETED	The Safety and Effectiveness of Low and High Carbohydrate Diets
NCT00115063	Phase 4	TERMINATED	LOSS- Louisiana Obese Subjects Study
NCT00134303	Phase 4	COMPLETED	Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity
NCT00143936	Phase 4	COMPLETED	The Safety and Efficacy of Low and High Carbohydrate Diets
NCT00143962	Phase 4	COMPLETED	Comparison of Two Approaches to Weight Loss Follow-Up Study
NCT00152360	Phase 4	COMPLETED	The Effect of Xenical on Weight and Risk Factors
NCT00176306	Phase 4	COMPLETED	Levofloxacin Pharmacokinetics (PK) in the Severely Obese
NCT00203450	Phase 4	COMPLETED	Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial
NCT00205504	Phase 4	COMPLETED	Oral Contraceptives in the Metabolic Syndrome
NCT00229229	Phase 4	TERMINATED	Comparison of 4 Diets in the Management of Overweight Patients With Vascular Disease
NCT00234988	Phase 4	COMPLETED	A Phase IV, Multi-Center, Open-Label Trial of Sibutramine in Combination With a Hypocaloric Diet in Obese and Overweight Thai Subjects.
NCT00264589	Phase 4	COMPLETED	Exercise Training and Cardiovascular Function in Obesity and in Type 2 Diabetes
NCT00288873	Phase 4	COMPLETED	Characterization of Hyperparathyroidism and Vitamin D Deficiency in Obesity
NCT00298857	Phase 4	TERMINATED	A Pharmacokinetic Study to Compare the Dosing of Valproic Acid in Subjects With Different Body Weights
NCT00315146	Phase 4	COMPLETED	Optimizing Body Composition for Function in Older Adults
NCT00319202	Phase 4	TERMINATED	Clinical Trial to Assess the Effects of Candesartan on the Carbohydrate Metabolism of Obese Subjects
NCT00327912	Phase 4	UNKNOWN	Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Biliopancreatic Diversion (BPD)- Duodenal Switch for Superobesity
NCT00352287	Phase 4	COMPLETED	Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults
NCT00353054	Phase 4	COMPLETED	Effect of Calcium/Vitamin D Supplementation on Body Weight and Fat Loss.
NCT00390637	Phase 4	COMPLETED	Diet, Obesity and Genes (DiOGenes)
NCT00415688	Phase 4	COMPLETED	Lifestyle Modification for Obesity-Related Type 2 Diabetes
NCT00433641	Phase 4	COMPLETED	Weight Loss in Response to Sibutramine (MERIDIA) is Influenced by the Inherited Genes
NCT00440375	Phase 4	COMPLETED	Effects of Rosiglitazone on Bone in Postmenopausal Diabetic Women
NCT00453557	Phase 4	COMPLETED	Mechanism of Growth Hormone Effects on Adipose Tissue
NCT00456885	Phase 4	COMPLETED	The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
NCT00463112	Phase 4	COMPLETED	Effect of Diet Plus Sibutramine on Hormonal and Metabolic Features in Overweight and Obese Women With PCOS
NCT00512187	Phase 4	COMPLETED	Moderate Weight Loss Makes Obese Patients With Severe Chronic Plaque Psoriasis Responsive to Sub-Optimal Dose of Cyclosporine: an Investigator Blinded, Controlled, Randomized Clinical Trial
NCT00516919	Phase 4	COMPLETED	Study of Behavioral Weight Loss Therapy for Obesity and Binge Eating in Monolingual Hispanic Persons
NCT00522470	Phase 4	COMPLETED	Effects of Rosiglitazone on Serum Ghrelin and Peptide YY Levels
NCT00537810	Phase 4	COMPLETED	Treatment of Binge Eating in Obese Patients in Primary Care
NCT00538486	Phase 4	COMPLETED	A Randomized, Double-Blind, Active Control Trial Comparing Effects of Telmisartan, Candesartan and Amlodipine, Alone or Plus Metformin, on Non-Diabetic, Obese Hypertensive Patients
NCT00584389	Phase 4	TERMINATED	The Effect of Rimonabant on Energy Expenditure, Fat Metabolism and Body Composition
NCT00585182	Phase 4	COMPLETED	Study to Evaluate Weight-based Enoxaparin Dosing in Obese Medical Patients at Risk for DVT
NCT00632840	Phase 4	COMPLETED	Pharmacological Regulation of Fat Transport in Metabolic Syndrome
NCT00636142	Phase 4	COMPLETED	Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity
NCT00675987	Phase 4	COMPLETED	A Randomized Clinical Trial To Study Losartan On Endothelial Dysfunction and Insulin Resistance In Obese Patients
NCT00694811	Phase 4	COMPLETED	Effects of Re-Feeding Duration on Weight Maintenance After Weight Loss With Very-Low-Energy Diets (VLEDs)
NCT00699413	Phase 4	TERMINATED	Supplements for Controlling Resistance to Insulin
NCT00729963	Phase 4	COMPLETED	Sibutramine Versus Continuous Positive Airway Pressure (CPAP)in Obstructive Sleep Apnea (OSA) Patients
NCT00752726	Phase 4	COMPLETED	Effect of Orlistat in Body Composition
NCT00770328	Phase 4	COMPLETED	The Effects of Pentoxifylline on PAI-1 in an Obese Population
NCT00775164	Phase 4	WITHDRAWN	Pioglitazone Therapy in Obese Children With Insulin Resistance: A Randomized, Controlled Pilot Study
NCT00775814	Phase 4	COMPLETED	Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
NCT00779844	Phase 4	TERMINATED	Anesthesic Propofol and Remifentanil Requirements in Obese Patients
NCT00788840	Phase 4	COMPLETED	Detemir Energy Expenditure Study
NCT00790946	Phase 4	UNKNOWN	Kagoshima Collaborate Trial in Metabolic Syndrome (KACT Study)
NCT00841217	Phase 4	COMPLETED	Regulation of Lipoprotein Transport in Metabolic Syndrome
NCT00845559	Phase 4	WITHDRAWN	The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults
NCT00847262	Phase 4	COMPLETED	Trial Comparing Metabolic Effects of Telmisartan and Amlodipine on Hypertensive Patients With Obesity and Diabetes
NCT00852384	Phase 4	COMPLETED	Non Invasive Pressure Support Ventilation (NIPPV) Versus Recruitment Maneuver (RM) and Preoxygenation
NCT00877123	Phase 4	COMPLETED	Effect of Vitamin D Supplementation on Fasting Glucose and Interleukin-10 (IL-10) in Arab Women With Impaired Fasting Glucose
NCT00883259	Phase 4	UNKNOWN	Metformin and Gestational Diabetes in High-risk Patients: a RCTs
NCT00917033	Phase 4	COMPLETED	Tracheal Intubation of Morbidly Obese Patients. GlideScope Versus Direct Laryngoscopy
NCT00928005	Phase 4	COMPLETED	Evaluating the Effects of a Diet and Exercise Program in People With Type 2 Diabetes or Prediabetes: (The SHAPE3 Study)
NCT00932022	Phase 4	COMPLETED	Trospium Chloride XR in Obese Female Patients With Overactive Bladder
NCT00934570	Phase 4	COMPLETED	Activity and Metformin Intervention in Obese Adolescents
NCT00943969	Phase 4	COMPLETED	Determinants of Oral Morphine Answer Among Obese Patients Before and After Gastric Bypass
NCT00959309	Phase 4	COMPLETED	Media Use in Preschooler Study (MUPS)
NCT00983970	Phase 4	COMPLETED	Effects of Interactive Video Game Cycling on Obese Adolescent Health

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for ANO2 across ~30M SureChEMBL compounds — explore on Sugi Predict.